Abstract The manufacturer of olaratumab (Lartruvo Ò
Introduction
Soft tissue sarcoma (STS) tumours are uncommon, accounting for approximately 1% of all cancers [1] . STSs are most often diagnosed in middle-aged and older adults, with approximately 43% of all sarcoma cases occurring in people over 65 years of age [2] . While STS can occur anywhere in the body (in muscles, blood vessels, fat tissue, or other mesenchymal [or connective] tissues that support, surround and protect the organs), three-quarters of STS tumours occur in the extremities [3] . There are over 50 histological types of STSs, which differ in terms of their tissue of origin, clinical behaviour, age of occurrence, aggressiveness, the way they spread, genetic alterations, and their sensitivity to certain therapies. The most common subtypes of STSs in the UK are leiomyosarcoma, fibroblastic sarcoma and liposarcoma [2] .
A number of STS classification systems have been proposed [4] [5] [6] (see Fletcher et al. [3] for a comparative analysis). The World Health Organization classification of soft tissue and bone tumours (2013) [3] classifies STS as benign, intermediate, or malignant; intermediate tumours are described as either locally aggressive or rarely metastasizing.
Surgery is the primary treatment for resectable local STS. The aim is to cure the disease by completely excising the tumour with a margin of normal tissue. Tumour resectability depends on the stage and anatomical location of the tumour, as well as the patient's comorbidities [1] . Radiotherapy is commonly used either prior to or after surgery in patients with grade 2 and 3 tumours [6] . For patients with STSs not amenable to surgery, observation is an option for asymptomatic disease. Symptomatic patients may be treated with chemotherapy, radiotherapy, palliative surgery, or best supportive care (BSC). The choice of treatment will take into account disease histology, distribution, volume, and likely sensitivity to systemic treatment.
Standard first-line chemotherapy treatment for advanced STSs, specified in the current UK guidelines for the management of STSs [1] , is single-agent doxorubicin; treatment with ifosfamide can also be offered if anthracyclines are contraindicated. Second-line therapies are ifosfamide, trabectedin, and the combination of gemcitabine and docetaxel. A number of other agents, such as dacarbazine and pazopanib, can be considered beyond second-line therapy, depending on patient fitness, comorbidity and funding provisions. Systemic anticancer treatment for advanced STSs is not curative, with a reported median survival time of 15-18 months [7] .
In a recent US study, an open-label, randomised, phase II trial (JGDG), the addition of olaratumab (Lartruvo Ò , Eli
Lilly & Company Limited, hereinafter referred to as Lilly) to doxorubicin chemotherapy for STS patients resulted in prolongation of overall survival (OS) of 11.8 months [8] .
Olaratumab is a monoclonal antibody that can bind to platelet-derived growth factor receptor-a (PDGFRa), a protein that plays an important role in cancer cell proliferation, and thus inhibit tumour growth. In September 2016, the European Medicines Agency recommended granting a conditional marketing authorisation to olaratumab, in combination with doxorubicin, for the treatment of adults with advanced STS, for whom surgery or radiotherapy is not suitable and who have not been previously treated with doxorubicin [9] .
The Decision Problem
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of olaratumab, Lilly, to submit evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for advanced STS not amenable to surgery or radiotherapy, as part of the Institute's Single Technology Appraisal (STA) process (for a description of the NICE STA process refer to the NICE guidelines [10] ). The Peninsula Technology Assessment Group, commissioned to act as the Evidence Review Group (ERG), critically reviewed the submitted evidence and conducted an additional analysis. The report was submitted to NICE on 9 March 2017, followed by an addendum with an additional analysis requested by NICE, which incorporated a discount offered by Lilly through a Commercial Access Agreement (CAA) with NHS England. The STA was completed in June 2017. Herein, we present a summary of the company's submission, the analysis prepared by the ERG, and the NICE guidance. For further details on this appraisal refer to the NICE website [11] .
The Evidence Review Group's (ERG's) Review
The company examined the clinical and cost effectiveness of combination treatment with olaratumab plus doxorubicin, hereinafter referred to as OlaDox, compared with treatments with doxorubicin only and ifosfamide plus doxorubicin (IfoDox), listed in NICE's final scope for this appraisal. Based on clinical advice, the IfoDox chemotherapy is rarely used for treating STS in the UK. Therefore, the NICE Appraisal Committee concluded that the most relevant comparator for OlaDox was doxorubicin chemotherapy, and did not consider IfoDox as a comparator in the Final Appraisal Determination. Nonetheless, we present clinical-and cost-effectiveness results for IfoDox as this comparator may be of relevance to healthcare systems in other countries. The company's evidence was submitted in anticipation that olaratumab would be considered as an alternative to doxorubicin, which has been used as a first-line treatment for advanced STS for over three decades. The company argued that since the maximum cumulative lifetime dose of doxorubicin allowed in UK clinical practice is 450 mg/m 2 (equal to six treatment cycles at a dose of 75 mg/m 2 ) [11] , patients who have already received doxorubicin in the firstline setting would not be eligible for OlaDox in subsequent lines of treatment.
Clinical Evidence Provided by the Company
A systematic literature review was conducted to identify randomised clinical trials of olaratumab and other interventions for the treatment of adult patients with advanced STS. The only clinical trial of olaratumab that had been identified and reported by Lilly in the clinical-effectiveness systematic review was an open-label, phase Ib (15 patients) and randomised phase II (133 patients) trial-JGDG (Lilly)-conducted in the US [8] . Data on the clinical effectiveness and safety of olaratumab in combination with doxorubicin, utilised in the company's economic analysis, were derived from the JGDG phase II trial, in which patients were randomised to OlaDox (n = 66) and doxorubicin monotherapy (n = 67); the dosage, route and duration of administration are detailed in Online Resource 1. Approximately 65% of patients in the pivotal trial received first-line therapy, while other patients received second-and third-line treatments (see our report for further details [11] ). In the trial, patients in the doxorubicin arm were allowed to receive olaratumab after discontinuing doxorubicin treatment (due to disease progression during or after completion of the initial treatment with the doxorubicin chemotherapy) until progressive disease, unacceptable toxicity or discontinuation for any other reason.
In patients who had no prior lines of therapy for advanced disease, an investigator-assessed improvement in median progression-free survival (PFS) was 2.5 months (6.6 months, 95% confidence interval [CI] 4.1-8.3) in the OlaDox arm versus 4.1 months (95% CI 2.8-5.4) in the doxorubicin arm (hazard ratio [HR] 0.672; p = 0.0615) [8] . All patients were followed for a minimum of 30 days after the last dose of olaratumab, and thereafter every 4-6 weeks until all olaratumab-related toxicities resolved, stabilised, returned to baseline, or were deemed irreversible. Patients were followed for survival at regularly scheduled intervals (approximately every 3 months) for at least 2 years. Treatment with OlaDox improved median OS in the intention to treat (ITT) population by 11.8 months compared with doxorubicin alone (26.5 More patients receiving doxorubicin than those receiving OlaDox discontinued the study treatment due to treatment emergent adverse events (16.4 vs. 7.6%). The most frequent grade 3 or higher adverse events, reported in the OlaDox and doxorubicin arms, were neutropenia (54.7 and 33.9%), anaemia (12.5 and 9.2%), and febrile neutropenia (12.5 and 13.8%), respectively.
A network meta-analysis was conducted to compare the effectiveness of OlaDox versus IfoDox since no trials had been identified in the systematic literature review that provide head-to-head evidence of the efficacy and safety of these treatments. This meta-analysis was implemented in WinBUGS. A network diagram is shown in Fig. 1 .
The analysis included data from six studies with seven treatments, six of which were relevant to the decision problem. With regard to the modelling of patients' survival, the company opted for the second-order fractional polynomials method; however, this method requires individual patient data, which were only available for the JGDG trial. Hence, for the remaining studies, individual patient data were reconstructed from digitised KaplanMeier (KM) plots and numbers at risk/numbers of events using the method described by Guyot et al. [17] . The fixedeffects modelling approach was adopted by the company because of its simplicity and transparency (the results of the analysis are confidential [11] ).
Critique of the Clinical Evidence
The company conducted a systematic literature review of clinical effectiveness in accordance with the NICE reference case [18] . The primary focus of the company's submission, the JGDG study, was generally an appropriately designed randomised controlled trial, although the study population was small, with only 133 patients, due to the rarity of STS. With regard to histological subtypes of STS, patients in the JGDG trial were representative of the UK population. Baseline characteristics were generally balanced in the OlaDox and doxorubicin treatment groups.
However, the protocol for doxorubicin monotherapy in the trial differed from UK practice; patients received up to eight cycles of doxorubicin as part of the combination treatment with OlaDox, while a maximum of six cycles of doxorubicin monotherapy is typically administered in the NHS.
Approximately 45% of participants in the doxorubicin arm subsequently received olaratumab monotherapy, which is a limitation to the study design due to confounding of outcome measures.
The open-label design of the trial, although unavoidable as the treatments generally require different levels of medical intervention, is likely to increase the risk of bias.
In the network meta-analysis, the company adopted the fixed-effects modelling approach, which the ERG considered appropriate.
Cost-Effectiveness Evidence Provided by the Company

Methods
Lilly conducted a systematic review of cost-effectiveness evidence. The searches did not identify any studies directly related to the decision problem. Therefore, the company developed a de novo economic model, which was informed by the JGDG study [8] ; a systematic review of countryspecific resource use, costs and utilities; the company's own observational study of resource cost and use specific to UK patients with advanced STS [11, 19] ; and multiple oncologists' and external consultants' advice on STS and model implementation.
A partitioned survival model [20] was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA), with a standard model structure that was used in numerous health technology assessments: 'Progressionfree', 'Progression' and 'Death' (Fig. 2 ). In the base-case analysis, patients entered the model upon commencement of first-line treatment. In progressive disease, patients received up to three further lines of therapy and BSC [21] . 'Death' was an absorbing state in this model.
The primary health outcomes were life-years (LYs) and quality-adjusted life-years (QALYs), attained in each treatment arm; the economic outcome was the incremental cost-effectiveness ratio (ICER). The model cycle length was 1 week. The baseline model time horizon was 25 years, which was justified as a lifetime horizon of patients with advanced STS, based on the OS data from the JGDG study, extrapolated beyond the study observation period of approximately 4 years. Due to the short model cycle, no half-cycle correction was implemented. In the base-case analysis, the perspective was of the NHS and Personal Social Services, and costs and benefits were discounted at 3.5% per year in accordance with the NICE reference case [18] .
3.2.1.1 Survival Estimates PFS for OlaDox versus doxorubicin was modelled using KM data for first-line patients, reported in the JGDG trial (Fig. 3a) . No extrapolation of PFS was performed since the data were mature. 6 Maurel et al. [16] . Doc docetaxel, Dox doxorubicin, Gem gemcitabine, GemDoc gemcitabine ? docetaxel, Ifo ifosfamide, IfoDox ifosfamide ? doxorubicin, Ola olaratumab, OlaDox olaratumab ? doxorubicin. Light blue, blue and grey shading correspond to Dox, OlaDox and IfoDox regimens, respectively
The effect of various parametric models for PFS on model predictions was explored in scenario analyses.
Log-cumulative hazard plots for OS were approximately parallel, and the company argued that this justified assuming proportional hazards for OS. Due to the small number of patients and events (i.e. deaths and censored observations) in the first-line subgroup of the JGDG study (40 patients and 21 events in the OlaDox arm, with 47 patients and 36 events in the doxorubicin arm), in the base case, the company employed the 'arms together' approach when modelling OS, i.e. parametric survival models were fitted to the ITT dataset with the line of therapy as a covariate; this approach allowed the inclusion of data on more patients compared with the 'individual arms' approach. Other covariates were sex, tumour type (leiomyosarcoma vs. other), Eastern Cooperative Oncology Group (ECOG), performance status (PS) [0 vs. 1 or 2], interactions between treatment and tumour type, and treatment and line of therapy. Patient's age and PDGFRa expression (positive vs. negative) were also explored for inclusion; however, they were found to be non-significant and were later removed from the parametric models to avoid model overfitting.
Several parametric models were fitted to the KM estimates of OS reported in the pivotal trial: exponential, Weibull, gamma, Gompertz, log-logistic and log-normal. Since the OS data were immature (the length of the observation period in the JGDG trial was 47 months), survival was extrapolated beyond the observation period to estimate the costs and effects of the treatments over the lifespan of patients with advanced STS. The company then used external evidence from Van Glabbeke et al. [22] to validate extrapolated OS for doxorubicin at 10 years after diagnosis of advanced disease. The company stated that selection of the parametric survival functions for inclusion in the company's economic model was based on Akaike information criterion (AIC), Bayesian information criterion (BIC), the visual fit to the KM curves and clinical plausibility. On the basis of these criteria, only the gamma function provided a plausible extrapolation for OS in doxorubicin patients. Of note, the predictions of the gamma model were 5 and 11% for patients receiving doxorubicin and OlaDox, respectively, surviving 10 years after the diagnosis of advanced STS; at approximately 25 years after diagnosis, virtually all patients have died.
Since it was not possible to predict survival beyond 10 years, either from the JGDG data set or the results of the study by Van Glabbeke et al. [22] , the company compared the hazard of death for patients from the Van Glabbeke study with patients from the general population of England and Wales of the same age and sex [23] . At the end of follow-up in the Van Glabbeke study, the hazard for death for patients with STS was 5.19-fold higher than that for the general population. Therefore, for the base-case analysis, for times after the end of follow-up, the HR of 5.19 was applied to the general mortality rates to account for the extra risk of death for cancer patients. The resulting OS curves based on the gamma model are shown in Fig. 3b .
In the pivotal trial, among the 67 patients in the doxorubicin arm, 30 patients received olaratumab monotherapy upon disease progression. The company examined a number of naive and more complex methods for the adjustment of treatment switching. Two methods, the rankpreserving structural failure time model (RPSFTM) and the iterative parameter estimation (IPE) algorithm, were deemed inappropriate since both methods critically rely on a limiting assumption of the 'common treatment effect', i.e. the treatment effect received by 'switchers' must be the same (relative to the time the treatment is taken for) as the treatment effect received by patients initially randomised to the experimental arm. This assumption is not valid for the JGDG trial as the treatments were different; in the experimental arm, the treatment was OlaDox followed by olaratumab monotherapy after discontinuation of doxorubicin (without progression) versus olaratumab monotherapy in the 'switchers' (following progression) from the control arm. The company also considered the inverse probability-of-censoring weights (IPCW) and the two-stage methods. These methods estimated HRs similar to the one from the ITT analysis. The company concluded that the control-arm patients who received olaratumab monotherapy had similar OS compared with patients who did not receive olaratumab after discontinuation of doxorubicin. Therefore, OS in doxorubicin patients was not adjusted for the post-progression olaratumab monotherapy, and no sensitivity analysis addressing potential uncertainty related to treatment switching was reported in the company's submission.
For the OlaDox versus IfoDox comparison, PFS and OS were derived from the network meta-analysis (Sect. 3.1) and were estimated from second-order fractional polynomials (Fig. 3c, d ) [11] . Due to the relatively small sample size in the JGDG trial, the entire ITT population dataset was utilised to estimate the fractional polynomial models rather than the data set for the first-line patient subgroup. The resulting hazard functions for both PFS and OS were based on median estimates of the coefficients of the fractional polynomials (for further details refer to Sect. 4.3 of our report [11] ).
Costs
Total costs in the company's model, reported in Great Britain pounds (GBP; 2015), included the costs of drug acquisition and administration, disease management, the cost of treating adverse events and cardiac monitoring costs (a detailed description is provided in Online Resource 2).
Olaratumab and granulocyte colony-stimulating factor (G-CSF; filgrastim) were administered based on a patient's weight; the doses of other drugs were administered proportional to body surface area (BSA). In the main analysis, the company assumed a mean weight of 77.3 kg referencing the GeDDiS trial, which was conducted mainly in the UK [12] ; a mean BSA of 1.91 m 2 was derived from the Health Survey of England (2013).
In the US-based JGDG trial, olaratumab was administered intravenously on days 1 and 8 of 21-day treatment cycles until disease progression; doxorubicin was administered intravenously once per 21-day treatment cycle for up to eight cycles or disease progression (a cumulative dose of 600 mg/m 2 ). Both treatments could be discontinued due to the occurrence of severe adverse events or other causes. To mitigate the risk of cardiotoxicity due to doxorubicin, patients could also receive the cardioprotectant dexrazoxane in cycles five-eight (Online Resource 1). UK and doxorubicin 75 mg/m 2 ? ifosfamide 10 g/m 2 (for which evidence was available) have similar efficacy. In addition, no data were available to estimate the extent of dose reduction for patients receiving IfoDox. Therefore, the company modelled the planned dose of IfoDox as in JGDG, while costing of OlaDox was based on the dose reported in the pivotal trial (Online Resource 2). The 20% decrease in IfoDox dose was explored in a sensitivity analysis.
The company assumed availability of 500 and 190 mg vial sizes of olaratumab (in anticipation of marketing authorisation for the 190 mg vial of olaratumab). In the company's model, no vial sharing was assumed for all intravenously administered drugs.
The costing of drug administration was based on the assumption that the OlaDox administration (with premedication for both drugs) can take up to 2 h, and administration of doxorubicin (including premedication) can take up to 60 min (relevant Healthcare Resource Group codes and costs per administration are provided in Tables 4 and  5 , Online Resource 2).
In the JGDG study, patients with advanced STS received up to four lines of systemic anticancer therapy after the study treatments. In the base case, the company assumed that the total treatment cost in progressive disease is independent of survival post-progression, i.e., the cost of post-progression treatment was identical in both treatment arms (Table 11 , Online Resource 2).
In the base-case analysis, the cost of treating grade 3 or higher adverse events was calculated by combining the proportion of events likely to require hospitalisation based on data from the JGDG trial, with the estimates of costs per event derived from NHS reference costs (Table 9 , Online Resource 2). The costs of managing adverse events were accounted for in the first year of the model.
Utilities
Since the JGDG trial did not collect any health-related quality of life (HRQoL) data, the company conducted a systematic literature review to identify published health-state utility estimates. The utility values of 0.72 and 0.56 reported by Reichardt et al. [24] were assumed in the base-case analysis for progression-free and progressed health states, respectively (Table 12 , Online Resource 2); they were measured from patients with metastatic STS and metastatic bone sarcoma with favourable response to chemotherapy, using EQ-5D. In the company's base case, disutilities arising from grade 3/4 adverse events were also accounted for and are listed in Table 8 (Online Resource 2).
Results
The mean OS of patients with advanced STS, predicted by the company's model, was 4.18 and 2.32 years in the OlaDox and doxorubicin arms, respectively. The OlaDox arm accrued the most QALYs (2.11), with 0.46 in the progression-free state and 1.66 in progressed disease; the doxorubicin arm had 1. Of note, in these analyses, the estimated OS for OlaDox patients differs (Fig. 3b, d ). The company argued that the network meta-analysis provided an adjusted indirect comparison based on average outcomes for doxorubicin rather than a naive comparison of individual trial arms [11] .
The base-case ICERs for both comparisons, estimated under the list price of olaratumab, are confidential. When the CAA discount proposed by the company was applied, the ICERs for OlaDox versus doxorubicin and IfoDox were £46,076 and £28,201 per QALY gained, respectively; the ICERs obtained in probabilistic sensitivity analyses were £47,127 and £30,604 per QALY; the respective probabilities of the OlaDox being cost effective at the threshold of £50,000/QALY gained were 0.54 and 0.88 (parametric uncertainty was represented with probability distributions; see Online Resource 2 and the NICE report [11] ). In the UK practice scenario analysis (with a maximum of six cycles of doxorubicin and the exclusion of dexrazoxane), the ICER for the OlaDox versus doxorubicin comparison decreased only slightly.
With regard to the deterministic sensitivity analysis and scenario analyses conducted by the company, the model inputs that had the greatest impact on the results were the parametric survival functions for the OlaDox versus doxorubicin comparison, plausible variations in the health-state utility values, and the cost of drug administration in post-progression health state. The CAA, the detailed results from the base-case, sensitivity and scenario analyses, constitute commercial-in-confidence information and are therefore not presented here.
Critique of the Cost-Effectiveness Evidence
The perspective of the NICE reference case [18] was adopted by the ERG when critiquing the company's economic evaluation. In this section, we highlight the key issues identified in the company's submission; for further details refer to our report to NICE [11] .
We consider the structure of the company's economic model appropriate and consistent with the natural history of advanced STS. However, we disagree with Lilly's selection of the gamma function as the best fit for the KM estimates of OS from the pivotal trial. The patient population in the study by Van Glabbeke et al. [22] , used by the company for external validation of extrapolated OS, was substantially younger than the population in the pivotal trial (with 75.5% of patients B60 years of age), which might overestimate the long-term survival of the patient population relevant to this appraisal. Based on our clinical expert's opinion, the lognormal distribution presented in the company's submission, among other candidate models for OS, would be more relevant to the decision problem since it provides more clinically reasonable prediction of 10-year survival in patients with advanced STS (Fig. 3b) . According to the log-normal model, 1.7% of doxorubicin patients and 4.3% of patients receiving OlaDox are expected to survive 10 years after the diagnosis of advanced disease, while the relevant predictions of the gamma model are higher, i.e. 5 and 11%.
Lilly underestimated drug administration costs by underestimating administration time for OlaDox and olaratumab monotherapy. We were advised by our clinical expert that the OlaDox administration (including premedication for olaratumab and doxorubicin) may take 2.5-3 h, and administration of olaratumab monotherapy (with premedication for olaratumab) may take up to 90 min (further details including a description of the relevant Healthcare Resource Group codes and costing of drug administration can be found in Online Resource 2).
When estimating the acquisition cost of olaratumab, the company assumed a mean patient weight of 77.3 kg, referencing the GeDDiS trial, conducted mainly in the UK [12] . Of note, the US-based JGDG study reported higher estimates of patients' mean weight, i.e. 85.8 kg (standard deviation [SD] 23.00) and 82.5 kg (SD 23.40) in the OlaDox and doxorubicin arms, respectively. The weight estimate from the company's model could not be verified by the ERG since the evidence source was available as an abstract only.
The health-state utility values in the company's basecase analysis were adopted from the study by Reichardt et al. [24] . The company acknowledged that the study selection criterion (i.e. favourable response to chemotherapy) may have resulted in higher utility values than would be expected for all STS patients with advanced disease. We believe that age heterogeneity may bias the results further since patients in the referred study were significantly younger than patients in the pivotal trial. In the evidence source, the mean age of patients at diagnosis was 49.5 (SD 17.1), while the mean age of patients from the OlaDox and comparator arms in the JGDG trial was 56.8 (SD 12.53) and 58.3 (SD 12.50), respectively.
Lilly examined the effect of the subsequent treatment with olaratumab monotherapy on survival outcome in the doxorubicin arm. The company's conclusion of no effect of olaratumab treatment on survival in the doxorubicin arm may not be valid due to a number of reasons, such as the small sample size, immaturity of survival data, and other assumptions made by the company (detailed in our report [11] ), which are not supported by data from the JGDG trial. This may further contribute to uncertainty in survival and therefore cost effectiveness.
The company's assumption made in the base-case that the cost of subsequent treatment does not depend on postprogression survival is not supported by the results of Lilly's observational study, reported by Mytelka et al. [19] , on which (as the company stated in the submission) the model parameterisation was based; data reported by the authors suggest that the drug costs increase substantially with the line of treatment.
Finally, the cost-effectiveness evidence of OlaDox compared with IfoDox, provided by the company, is highly uncertain since it was based on an indirect comparison. Importantly, the survival curves in the company's model were estimated from the median values of the coefficients of the fractional polynomials obtained in the network metaanalysis (not mean values), which is not in line with the NICE reference case [18] .
Additional Work Undertaken by the ERG
As a result of our critique of the company's submission to NICE, we developed our base case by adjusting the relevant items in the company's model ( Table 1) .
The ERG's mean base-case ICER for the OlaDox versus doxorubicin comparison (Table 1 ) was higher (approximately £60,000 per QALY gained) compared with the company's ICER of £46,076 per QALY, due to differences in (1) extrapolation of OS, (2) drug administration costs, and (3) the assumption on the mean patients' weight used to estimate the cost of drug acquisition. Assuming the lognormal model for OS (Fig. 3b) , longer administration time for OlaDox and doxorubicin, and a mean patient weight of 82.5 kg (as per the JGDG trial) increased the ICER for OlaDox versus doxorubicin from £46,076 to approximately £60,000 per QALY gained. The ERG's base-case ICER for OlaDox versus IfoDox was also higher than the company's estimate (Online Resource 3). The increase in the ICER was primarily driven by the difference in drug administration costs.
We conducted deterministic and probabilistic sensitivity analyses for our preferred base-case ICERs. The model predictions were most sensitive to changes in the healthstate utility values, the OS models, and the assumption on the cost of treatment post-progression [11] . Probabilistic sensitivity analyses yielded ICERs similar to the base-case values (the results are confidential).
End-of-Life Criteria
Lilly argued that the presented evidence supported inclusion of olaratumab into NICE's end-of-life treatments since, first, the life expectancy for patients treated with the comparators is under 24 months and, second, there is sufficient evidence, based on Tap et al. [8] , for the intervention to increase patients' survival by at least 3 months. Of note, the JGDG study reported a median OS of 14.7 months in patients receiving standard-of-care doxorubicin, and improvement in median OS of 11.8 months in patients treated with OlaDox compared with doxorubicin.
However, the ERG noted that estimates of life expectancy, i.e. mean survival, should have been considered in the end-of-life analysis in accordance with the NICE guidance [18] . In the company's base case, the predicted life expectancy of patients receiving doxorubicin and IfoDox was 2.32 and 2.67 years, respectively, therefore the criterion of short life expectancy would not have been met, olaratumab would not qualify for the end-of-life category, and the cost-effectiveness threshold of £30,000 per QALY gained would be applicable.
Unlike the company's base case, the ERG's main analysis predicted life expectancy of 1.83 years for patients receiving doxorubicin; hence, the short life expectancy criterion was likely to be met. In addition, as shown in the JGDG trial, treatment with olaratumab is highly likely to prolong patients' survival, on average, by more than 3 months, signifying that OlaDox also meets the extensionto-life criterion. Therefore, combination therapy with olaratumab and doxorubicin seems to qualify as an end-oflife treatment; however, this conclusion is based on the model predictions which are highly uncertain due to immaturity of survival data reported in the pivotal JGDG trial.
Conclusions of the ERG Report
The only randomised controlled trial of olaratumab, JGDG, used by Lilly in the analysis, had a small patient population of 133 patients. Survival data were immature since approximately 40 and 20% of patients in the OlaDox and doxorubicin treatment arms, respectively, were alive at the end of the study. The OS estimates available for approximately 4 years were extrapolated by the company up to 25 years and externally validated on survival data for a substantially younger population. Therefore, due to the limitations in the clinical effectiveness evidence base, the estimates of the cost effectiveness of olaratumab plus doxorubicin are highly uncertain.
Based on the available evidence, olaratumab is likely to fulfil NICE's end-of-life criteria. However, the combination treatment with olaratumab is not cost effective, under the CAA proposed by the company, at the threshold of £50,000 per QALYgained usually considered by NICE when appraising end-of-life treatments.
National Institute for Health and Care
Excellence Guidance
In March 2016, the NICE Appraisal Committee reviewed the evidence available on the clinical and cost effectiveness of olaratumab in combination with doxorubicin for advanced STS. The Committee acknowledged that the Table 4 , Online Resource 2)
Overall effect of 1, 2 and 3 £60,000 £46,076
CAA Commercial Access Agreement, Dox doxorubicin, ERG Evidence Review Group, HRG Healthcare Resource Group, ICER incremental cost-effectiveness ratio, OlaDox olaratumab ? doxorubicin, OS overall survival, QALY quality-adjusted life-year a In our base case, we assumed that 500 and 190 mg vials of olaratumab are available main driver of the cost effectiveness of the combination therapy was the extrapolation of immature OS data. Based on clinical advice, the company's estimates of OS for both OlaDox and doxorubicin were considered by the committee as over-optimistic, and those from the ERG's analysis were regarded as more plausible. The committee agreed with the ERG on the use of higher drug administration costs compared with those presented by the company, and considered the mean patient weight assumed in the company's analysis was reasonable. The Committee concluded that the most plausible ICER for the OlaDox versus doxorubicin comparison is likely to be closer to the ERG's estimate of £60,000 per QALY gained than the estimate of £46,076 reported by the company. It considered that the combination treatment is likely to meet the end-of-life criteria. Based on the available evidence, the committee could not recommend olaratumab for routine use in the NHS [7] ; however, the committee acknowledged that olaratumab has the potential to be cost effective. It was aware that further data from the ANNOUNCE trial are anticipated to be available in December 2020 [25] . The committee understood that NICE, NHS England and the company would undertake further discussions to formalise the Access Agreement prior to publication of the guidance. The committee therefore recommended that olaratumab be used in the UK Cancer Drugs Fund if the conditions in the Access Agreement are followed. NICE's Final Appraisal Determination was published on 9 June 2017 [7] .
Conclusions
Olaratumab in combination with doxorubicin is recommended for untreated, advanced STS through the UK Cancer Drugs Fund until further evidence on survival and HRQoL being collected in the ANNOUNCE trial becomes available in December 2020.
